A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma

被引：0
|
作者：
Tulpule, A [1 ]
Khan, AU [1 ]
Mohrbacher, AF [1 ]
Espina, BM [1 ]
Buchanan, L [1 ]
Berman, N [1 ]
Gorospe, G [1 ]
Boswell, WD [1 ]
Nathwani, BN [1 ]
Levine, AM [1 ]
机构：
[1] USC, Keck Sch Med, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6688
引用
收藏
页码：604S / 604S
页数：1
相关论文
共 50 条
  • [21] Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin's lymphoma: A systematic review and meta-analysis
    Lu, Bin
    Shen, Longfei
    Ma, Ying
    Qi, Jia
    Li, Yulin
    Wang, Zhihao
    Han, Lu
    Zhong, Ming
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [22] Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma - A multicenter phase II study
    Bergmann, L
    Karakas, T
    Lautenschlager, G
    Jager, E
    Knuth, A
    Mitrou, PS
    Hoelzer, D
    ANNALS OF ONCOLOGY, 1995, 6 (10) : 1019 - 1024
  • [23] Cyclophosphamide, pegylated liposomal doxorubicin (Caely®), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma:: results from a prospective phase II study
    Martino, R
    Perea, G
    Caballero, MD
    Mateos, MV
    Ribera, JM
    de Oteyza, JP
    Arranz, R
    Terol, MJ
    Sierra, J
    San Miguel, JF
    HAEMATOLOGICA, 2002, 87 (08) : 822 - 827
  • [24] Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
    Younes, Anas
    Sehn, Laurie H.
    Johnson, Peter
    Zinzani, Pier Luigi
    Hong, Xiaonan
    Zhu, Jun
    Patti, Caterina
    Belada, David
    Samoilova, Olga
    Suh, Cheolwon
    Leppae, Sirpa
    Rai, Shinya
    Turgut, Mehmet
    Jurczak, Wojciech
    Cheung, Matthew C.
    Gurion, Ronit
    Yeh, Su-Peng
    Lopez-Hernandez, Andres
    Duehrsen, Ulrich
    Thieblemont, Catherine
    Chiattone, Carlos Sergio
    Balasubramanian, Sriram
    Carey, Jodi
    Liu, Grace
    Shreeve, S. Martin
    Sun, Steven
    Zhuang, Sen Hong
    Vermeulen, Jessica
    Staudt, Louis M.
    Wilson, Wyndham
    Fisher, Richard I.
    Engert, Andreas
    Stadtmauer, Edward A.
    Wei, Lee-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) : 1285 - +
  • [25] Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)
    M. Herold
    A. Schulze
    D. Niederwieser
    A. Franke
    H. J. Fricke
    P. Richter
    M. Freund
    B. Ismer
    K. Dachselt
    C. Boewer
    V. Schirmer
    J. Weniger
    R. Pasold
    C. Winkelmann
    C. Klinkenstein
    M. Schulze
    H. Arzberger
    K. Bremer
    S. Hahnfeld
    A. Schwarzer
    C. Müller
    Chr. Müller
    Journal of Cancer Research and Clinical Oncology, 2006, 132 : 105 - 112
  • [26] Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma
    Borchmann, Peter
    Herbrecht, Raoul
    Wilhelm, Martin
    Morschhauser, Franck
    Hess, Georg
    Cernohous, Paul
    Veals, Susan A.
    Singer, Jack W.
    Engert, Andreas
    LEUKEMIA & LYMPHOMA, 2011, 52 (04) : 620 - 628
  • [27] Liposomal doxorubicin (TLC D-99), cyclophosphamide, oncovin and prednisone (COP) in the treatment of aggressive non-Hodgkin's lymphomas (NHL).
    Levine, AM
    Tulpule, A
    Espina, BM
    Buchanan, LH
    Africano, M
    Boswell, W
    Welles, L
    BLOOD, 2000, 96 (11) : 137A - 137A
  • [28] Reduced dose of non-pegylated liposomal doxorubicin with cyclophosphamide, vincristine and prednisone ± rituximab for previously untreated elderly patients with aggressive lymphoma non suitables for standard chemotherapy
    Gimeno, E.
    Alvarez, A.
    Pedro, C.
    Abella, E.
    Gomez, M.
    Comin, J.
    Sanchez, B.
    Besses, C.
    Salar, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 218 - 218
  • [29] REDUCED DOSE OF NON-PEGYLATED LIPOSOMAL DOXORUBICIN WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND PREDNISONE RITUXIMAB FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH AGGRESSIVE LYMPHOMA NON SUITABLES FOR STANDARD CHEMOTHERAPY
    Gimeno, E.
    Alvarez, A.
    Pedro, C.
    Abella, E.
    Gomez, M.
    Comin, J.
    Sanchez, B.
    Gimenez, T.
    Besses, C.
    Salar, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 502 - 502
  • [30] Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma:: results of a randomised phase III trial (OSHO# 19)
    Herold, M
    Schulze, A
    Niederwieser, D
    Franke, A
    Fricke, HJ
    Richter, P
    Freund, M
    Ismer, B
    Dachselt, K
    Boewer, C
    Schirmer, V
    Weniger, J
    Pasold, R
    Winkelmann, C
    Klinkenstein, C
    Schulze, M
    Arzberger, H
    Bremer, K
    Hahnfeld, S
    Schwarzer, A
    Müller, C
    Müller, C
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (02) : 105 - 112
12345